Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luisa Castro-Laria

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Inflammatory Bowel Diseases|May 26, 2020
Erythema Nodosum: As an Extraintestinal Manifestation or Complication in Ulcerative Colitis?Teresa Valdés Delgado, Belén Maldonado Pérez, Luisa Castro Laria
Therapeutic Advances in Gastroenterology|September 1, 2023
Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosingFederico Argüelles-Arias, Teresa Valdés Delgado, Belén Maldonado Pérez, et al.
Revista Espanola De Enfermedades Digestivas|June 16, 2017
A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patientsBlas José Gómez Rodríguez, Luisa Castro Laria, Federico Argüelles Arias, et al.
Revista Espanola De Enfermedades Digestivas|May 5, 2021
Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pyloriCarolina Moreno Márquez, Paula Fernández Álvarez, Teresa Valdés Delgado, et al.
Revista Espanola De Enfermedades Digestivas|June 25, 2020
Vedolizumab response in inflammatory bowel disease. Two years of follow-upPilar Del Pino Bellido, María Belvis Jiménez, Luisa Castro Laria, et al.
Gastroenterology Research and Practice|April 18, 2014
Capsule endoscopy in the small bowel Crohn's diseaseFederico Argüelles-Arias, Juan Rodríguez-Oballe, Calixto Duarte-Chang, et al.
Revista Espanola De Enfermedades Digestivas|December 29, 2020
Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey resultsPaula Fernández Álvarez, María Belvis Jiménez, Belén Maldonado Pérez, et al.
Revista Espanola De Enfermedades Digestivas|September 14, 2021
Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary resultsFederico Argüelles-Arias, Paula Fernández Álvarez, Luisa Castro Laria, et al.
Therapeutic Advances in Gastroenterology|October 18, 2024
Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel diseasePilar Navajas Hernández, Samer Mouhtar El Halabi, Ana Caridad González Parra, et al.
Revista Espanola De Enfermedades Digestivas|September 21, 2020
Cut-off ranges of infliximab serum levels in Crohn's disease in the clinical practiceTeresa Valdés Delgado, María Fernanda Guerra Veloz, Luisa Castro Laria, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Inflammatory Bowel Diseases|May 26, 2020
Erythema Nodosum: As an Extraintestinal Manifestation or Complication in Ulcerative Colitis?Teresa Valdés Delgado, Belén Maldonado Pérez, Luisa Castro Laria
Therapeutic Advances in Gastroenterology|September 1, 2023
Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosingFederico Argüelles-Arias, Teresa Valdés Delgado, Belén Maldonado Pérez, et al.
Revista Espanola De Enfermedades Digestivas|June 16, 2017
A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patientsBlas José Gómez Rodríguez, Luisa Castro Laria, Federico Argüelles Arias, et al.
Revista Espanola De Enfermedades Digestivas|May 5, 2021
Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pyloriCarolina Moreno Márquez, Paula Fernández Álvarez, Teresa Valdés Delgado, et al.
Revista Espanola De Enfermedades Digestivas|June 25, 2020
Vedolizumab response in inflammatory bowel disease. Two years of follow-upPilar Del Pino Bellido, María Belvis Jiménez, Luisa Castro Laria, et al.
Gastroenterology Research and Practice|April 18, 2014
Capsule endoscopy in the small bowel Crohn's diseaseFederico Argüelles-Arias, Juan Rodríguez-Oballe, Calixto Duarte-Chang, et al.
Revista Espanola De Enfermedades Digestivas|December 29, 2020
Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey resultsPaula Fernández Álvarez, María Belvis Jiménez, Belén Maldonado Pérez, et al.
Revista Espanola De Enfermedades Digestivas|September 14, 2021
Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary resultsFederico Argüelles-Arias, Paula Fernández Álvarez, Luisa Castro Laria, et al.
Therapeutic Advances in Gastroenterology|October 18, 2024
Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel diseasePilar Navajas Hernández, Samer Mouhtar El Halabi, Ana Caridad González Parra, et al.
Revista Espanola De Enfermedades Digestivas|September 21, 2020
Cut-off ranges of infliximab serum levels in Crohn's disease in the clinical practiceTeresa Valdés Delgado, María Fernanda Guerra Veloz, Luisa Castro Laria, et al.
Pageof 3